Imunon (IMNN) Competitors $7.00 -0.55 (-7.24%) Closing price 04:00 PM EasternExtended Trading$6.98 -0.02 (-0.29%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. COEP, XLO, LVTX, HYPD, KALA, ITRM, AKTX, MAAQ, KPTI, and SNYRShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Coeptis Therapeutics (COEP), Xilio Therapeutics (XLO), LAVA Therapeutics (LVTX), Hyperion DeFi (HYPD), KALA BIO (KALA), Iterum Therapeutics (ITRM), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Karyopharm Therapeutics (KPTI), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Its Competitors Coeptis Therapeutics Xilio Therapeutics LAVA Therapeutics Hyperion DeFi KALA BIO Iterum Therapeutics Akari Therapeutics Mana Capital Acquisition Karyopharm Therapeutics Synergy CHC Imunon (NASDAQ:IMNN) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Do analysts rate IMNN or COEP? Imunon presently has a consensus target price of $232.50, suggesting a potential upside of 3,221.43%. Given Imunon's stronger consensus rating and higher possible upside, research analysts clearly believe Imunon is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IMNN or COEP more profitable? Coeptis Therapeutics' return on equity of -282.39% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -427.98% -175.03% Coeptis Therapeutics N/A -282.39%-127.23% Which has preferable earnings and valuation, IMNN or COEP? Coeptis Therapeutics has lower revenue, but higher earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K245.56-$18.62M-$1.36-5.15Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.01 Does the media favor IMNN or COEP? In the previous week, Imunon had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 6 mentions for Imunon and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.28 beat Imunon's score of -0.19 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, IMNN or COEP? Imunon has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Do insiders & institutionals have more ownership in IMNN or COEP? 4.5% of Imunon shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 6.0% of Imunon shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryImunon beats Coeptis Therapeutics on 8 of the 15 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.78M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-5.1521.1828.1120.03Price / Sales245.56337.65460.63103.88Price / CashN/A43.2336.5559.01Price / Book24.148.368.655.90Net Income-$18.62M-$55.19M$3.25B$258.66M7 Day Performance-15.46%5.89%4.20%2.23%1 Month Performance-44.16%17.63%10.83%12.77%1 Year Performance-59.42%5.10%34.67%19.36% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon1.9479 of 5 stars$7.00-7.2%$232.50+3,221.4%-58.4%$122.78M$500K-5.1530Stock SplitCOEPCoeptis Therapeutics0.6865 of 5 stars$10.70+0.2%N/A+117.3%$37.53MN/A-1.842Positive NewsGap UpXLOXilio Therapeutics2.721 of 5 stars$0.70-3.4%$4.00+473.5%-26.2%$37.39M$6.34M-0.8370Positive NewsLVTXLAVA Therapeutics2.3671 of 5 stars$1.44+1.4%$3.17+119.9%-27.7%$37.35M$11.98M-1.3860Positive NewsHYPDHyperion DeFi1.1268 of 5 stars$11.64-9.6%$2.00-82.8%-92.8%$37.13M$60K-0.2040Positive NewsGap UpKALAKALA BIO3.9657 of 5 stars$5.70-0.7%$13.00+128.1%-0.3%$37.04MN/A-0.6930ITRMIterum Therapeutics2.05 of 5 stars$0.87-5.0%$9.00+933.3%-34.3%$36.66MN/A-0.8810Positive NewsAKTXAkari Therapeutics2.6506 of 5 stars$1.14+0.4%$5.00+340.5%-71.9%$36.36MN/A0.009High Trading VolumeMAAQMana Capital AcquisitionN/A$4.30-6.9%N/A+812.7%$34.94MN/A0.001Gap UpKPTIKaryopharm Therapeutics3.8298 of 5 stars$4.02+4.4%$37.40+830.3%-68.8%$33.26M$145.24M-0.30380SNYRSynergy CHC4.0617 of 5 stars$3.50-3.0%$10.00+185.7%N/A$33.19M$33.59M0.0040 Related Companies and Tools Related Companies COEP Competitors XLO Competitors LVTX Competitors HYPD Competitors KALA Competitors ITRM Competitors AKTX Competitors MAAQ Competitors KPTI Competitors SNYR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
